These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16813566)

  • 1. Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library.
    Jensen JK; Malmendal A; Schiøtt B; Skeldal S; Pedersen KE; Celik L; Nielsen NC; Andreasen PA; Wind T
    Biochem J; 2006 Nov; 399(3):387-96. PubMed ID: 16813566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein.
    Andersen OM; Petersen HH; Jacobsen C; Moestrup SK; Etzerodt M; Andreasen PA; Thøgersen HC
    Biochem J; 2001 Jul; 357(Pt 1):289-96. PubMed ID: 11415462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor.
    Nykjaer A; Kjøller L; Cohen RL; Lawrence DA; Garni-Wagner BA; Todd RF; van Zonneveld AJ; Gliemann J; Andreasen PA
    J Biol Chem; 1994 Oct; 269(41):25668-76. PubMed ID: 7929271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein.
    Kasza A; Petersen HH; Heegaard CW; Oka K; Christensen A; Dubin A; Chan L; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(2):270-81. PubMed ID: 9346278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW; Simonsen AC; Oka K; Kjøller L; Christensen A; Madsen B; Ellgaard L; Chan L; Andreasen PA
    J Biol Chem; 1995 Sep; 270(35):20855-61. PubMed ID: 7657671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
    Croucher D; Saunders DN; Ranson M
    J Biol Chem; 2006 Apr; 281(15):10206-13. PubMed ID: 16459332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
    Bu G; Maksymovitch EA; Schwartz AL
    J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein.
    Stefansson S; Muhammad S; Cheng XF; Battey FD; Strickland DK; Lawrence DA
    J Biol Chem; 1998 Mar; 273(11):6358-66. PubMed ID: 9497365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.
    Wind T; Hansen M; Jensen JK; Andreasen PA
    Biol Chem; 2002 Jan; 383(1):21-36. PubMed ID: 11928815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes.
    Nykjaer A; Petersen CM; Møller B; Jensen PH; Moestrup SK; Holtet TL; Etzerodt M; Thøgersen HC; Munch M; Andreasen PA
    J Biol Chem; 1992 Jul; 267(21):14543-6. PubMed ID: 1378833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.
    Migliorini M; Li SH; Zhou A; Emal CD; Lawrence DA; Strickland DK
    J Biol Chem; 2020 Jan; 295(1):212-222. PubMed ID: 31792055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
    Stefansson S; Kounnas MZ; Henkin J; Mallampalli RK; Chappell DA; Strickland DK; Argraves WS
    J Cell Sci; 1995 Jun; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.
    Jensen JK; Durand MK; Skeldal S; Dupont DM; Bødker JS; Wind T; Andreasen PA
    FEBS Lett; 2004 Jan; 556(1-3):175-9. PubMed ID: 14706846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The High Affinity Binding Site on Plasminogen Activator Inhibitor-1 (PAI-1) for the Low Density Lipoprotein Receptor-related Protein (LRP1) Is Composed of Four Basic Residues.
    Gettins PG; Dolmer K
    J Biol Chem; 2016 Jan; 291(2):800-12. PubMed ID: 26555266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.